Medicare Part B Oral Drug Demo Project Falling Short Of Expectations
This article was originally published in The Pink Sheet Daily
The Centers for Medicare & Medicaid Services' oral drug replacement demonstration project is falling short of expectations, demo administrator Caremark said
You may also be interested in...
Caremark/AdvancePCS will administer the drug benefit for the oral chemotherapy demonstration, while South Carolina Blues subsidiary Trailblazer will handle enrollment, eligibility and education. CMS expects the demo to be enrolling patients by mid-July.
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products